News
We thank DCAT for the opportunity to share our capability and capacity expansion plan at the Member Company Announcement Forum during DCAT week last month. We hope our investment across API…
We thank DCAT for the opportunity to share our capability and capacity expansion plan at the Member Company Announcement Forum during DCAT week last month. We hope our investment across API and drug product for small molecule, oligonucleotide, peptide, and their conjugates will enable more novel medicines to the global market faster.
Read the announcement summary here: https://www.dcatvci.org/supplier-news/wuxi-sta-outlines-major-expansion-plans/
To view more news and webinars, please follow our LinkedIn page.
Keep reading
Shanghai, China – April 1, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences…
Couvet, Switzerland – November 14, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life…
First operational building dedicated to API development for oligonucleotides, peptides, and complex synthetic conjugates.
How can we help?
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA